Glioblastoma and other primary brain malignancies in adults: a review
LR Schaff, IK Mellinghoff - Jama, 2023 - jamanetwork.com
Importance Malignant primary brain tumors cause more than 15 000 deaths per year in the
United States. The annual incidence of primary malignant brain tumors is approximately 7 …
United States. The annual incidence of primary malignant brain tumors is approximately 7 …
Glioma targeted therapy: insight into future of molecular approaches
Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
M Lim, M Weller, A Idbaih, J Steinbach… - Neuro …, 2022 - academic.oup.com
Background Nearly all patients with newly diagnosed glioblastoma experience recurrence
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …
Emerging therapies for glioblastoma: current state and future directions
L Rong, N Li, Z Zhang - Journal of Experimental & Clinical Cancer …, 2022 - Springer
Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …
extremely poor prognosis. Given the poor survival with currently approved treatments for …
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing
great interest in the neuro-oncology community. While several reports show that subsets of …
great interest in the neuro-oncology community. While several reports show that subsets of …
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future …
PY Wen, M Weller, EQ Lee, BM Alexander… - Neuro …, 2020 - academic.oup.com
Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …
cause of morbidity and mortality. In recent years there have been important advances in …
Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells
Brain malignancies encompass a range of primary and metastatic cancers, including low-
grade and high-grade gliomas and brain metastases (BrMs) originating from diverse …
grade and high-grade gliomas and brain metastases (BrMs) originating from diverse …
Neoadjuvant checkpoint blockade for cancer immunotherapy
BACKGROUND Immunotherapies that target the interaction of programmed death 1 (PD-1)
with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 …
with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 …
[HTML][HTML] Immunotherapy for glioma: current management and future application
Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells.
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …